MedTrace Logo

Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations

NCT01206049 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2017-03-13

No results posted yet for this study

Summary

The purpose of this study is to determine the rate of progression free survival of patients with inoperable cholangiocarcinoma 6 months after enrollment in the study. The patients are treated with combination chemotherapy supplemented by biological agents panitumumab or bevacizumab.

Conditions

Interventions

DRUG

Gemcitabine

1,000 mg/m2 on day 1 of a 2 weeks cycle

DRUG

Oxaliplatin

60 mg/m2 on day 1 of a 2 weeks cycle

DRUG

Capecitabine

1,000 mg/m2 x 2 daily on days 1-7 of a 2 weeks cycle

DRUG

Panitumumab

6 mg/kg on day 1 of a 2 weeks cycle

DRUG

Bevacizumab

10 mg/kg on day 1 of a 2 weeks cycle

Sponsors & Collaborators

  • Vejle Hospital

    lead OTHER

Principal Investigators

  • Anders Jakobsen, MD, DMSc · Department of Oncology, Vejle Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01206049 on ClinicalTrials.gov